€1.2m · Pre-Seed · Software · Berlin, Germany
Berlin-based sci2sci has raised €1.2m in pre-seed funding, co-led by Heliad and IBB Ventures, with Robin Capital and Superangels participating. The company will use the capital to expand its engineering team and accelerate deployment of VectorCat and Integrity Cortex across biopharma and other regulated industries, according to IBB Ventures.
Making every AI claim traceable
Biopharma teams work across research papers, lab records, spreadsheets, network drives and specialist systems. When those sources conflict or change, an AI-generated answer can be difficult to defend in an audit or regulatory submission. sci2sci is building two connected products around that problem.
VectorCat catalogues data across existing storage systems without requiring a wholesale migration. Integrity Cortex then represents facts, claims and their relationships in a formal system where each claim must point to source evidence and each derived conclusion can be checked. The company says the product can also trace which downstream conclusions are affected when a source changes.
That architecture shifts the sales proposition away from producing fluent answers and towards reducing verification work. A regulated customer still has to validate the software, integrations and operating controls, but the product is designed to make an answer’s evidence chain inspectable rather than asking reviewers to trust a model’s prose.
Production deployments are the commercial test
IBB Ventures says sci2sci already works across pre-clinical research, contract clinical research and bioprocess operations. Heliad says the platform is running in production inside a listed global biopharma company, although neither investor names customers or discloses revenue. The company has also released its underlying Parseltongue framework under an Apache 2.0 licence.
The funding is therefore aimed at deepening deployments rather than proving only a technical concept. Hiring engineers can widen product coverage and integrations, while live customer work should show whether the verification layer can fit existing scientific and compliance processes without becoming another isolated data system.
sci2sci also plans to take the approach into other regulated sectors, including banking. The near-term execution test is more specific: turn initial biopharma use into repeatable deployments where customers can measure faster evidence tracing, fewer unresolved inconsistencies or less manual audit preparation. That proof will matter more than the breadth of industries the company could eventually serve.
Sources checked:
IBB Ventures · sci2sci · Heliad · Tech.eu Funding Explorer
